Pharmacologic management of the spastic and dystonic upper limb in children with cerebral palsy

Hand Clinics

Volumn 19, Issue 4, 2003, Pages 585-589

  O'Flaherty, Stephen ^a   Waugh, Mary Clare ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A; CARBAMAZEPINE; CARBIDOPA; CLONAZEPAM; CLONIDINE; CYPROHEPTADINE; DANTROLENE; DIAZEPAM; GABAPENTIN; HALOPERIDOL; LEVODOPA; TETRABENAZINE; TIZANIDINE; TRIHEXYPHENIDYL;

ARM; ATAXIA; CEREBRAL PALSY; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DROWSINESS; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DYSTONIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSALIVATION; HYPOTENSION; INSOMNIA; QUALITY OF LIFE; REVIEW; SEDATION; SEIZURE THRESHOLD; SIDE EFFECT; SPASTICITY; URINE RETENTION; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0142231991     PISSN: 07490712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0712(03)00061-1     Document Type: Review

References (41)

1. Boyd RN, Morris ME, Graham HK. Management of upper limb dysfunction in children with cerebral palsy: a systematic review. Eur J Neurol 2001; 8(Suppl 5):S150-66.
2. Kupsch A, Kuehn A, Klaffke S, Meissner W, Harnack D, Winter C, et al. Deep brain stimulation in dystonia. J Neurol 2003;250(Suppl 1): 147-52.
3. Krack P, Vercueil L. Review of the functional surgical treatment of dystonia. Eur J Neurol 2001; 8(5):389-99.
4. Graham HK, Aoki KR, Autti-Ramo I, Boyd RN, Delgado MR, Gaebler-Spira DJ, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000; 11(1):67-79.
5. Graham HK, Boyd RN, Fehlings D. Does intramuscular botulinum toxin A injection improve upper-limb function in children with hemiplegic cerebral palsy? Med J Aust 2003;178(2):95-6.
6. Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK. Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol 1997;39(3):185-93.
7. Wallen M, O'Flaherty S, Waugh M. Functional outcomes of intra-muscular Botulinum toxin A in the upper limbs of children with cerebral palsy: a phase II trial. Arch Phys Med Rehabil 2003; In press.
8. Koman KA, Mooney JF, Paterson Smith B. Neuromuscular blockade in the management of cerebral palsy. J Child Neurol 1996;11 (Suppl 1):S23-8.
9. Glenn MB. Nerve blocks. In: Glenn MB, Whyte J, editors. The practical management of spasticity in children and adults. Philadelphia: Lea & Febiger; 1990. p. 227-58.
10. SCPE. (Surveillance of Cerebral Palsy in Europe). Prevalence and characteristics of children with cerebral palsy in Europe. Dev Med Child Neurol 2002;44(9):633-40.
11. Matthews DJ, Wilson P. Cerebral palsy. In: Molnar GE, Alexander MA, editors. Pediatric rehabilitation. 3rd edition. Philadelphia: Hanley and Belfus; 1999. p. 193-217.
12. Abbruzzese G. The medical management of spasticity. Eur J Neurol 2002;9(Suppl 1):S30-4 discussion 53-61.
13. Lance JW. What is spasticity? Lancet 1990; 335(8689):606.
14. Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. Task Force on Childhood Motor Disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003; 111(1):89-97.
15. Langlois M, Richer F, Chouinard S. New perspectives on dystonia. Can J Neurol Sci 2003;30(Suppl 1): S34-44.
16. Gormley ME Jr, Krach LE, Piccini L. Spasticity management in the child with spastic quadriplegia. Eur J Neurol 2001;8(Suppl 5):S127-35.
17. Krach LE. Pharmacotherapy of spasticity: oral medications and intrathecal baclofen. J Child Neurol 2001;16(1):31-6.
18. Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: general and regional treatments. Muscle Nerve Suppl 1997;6:S92-120.
19. Joynt RL, Leonard JA Jr. Dantrolene sodium suspension in treatment of spastic cerebral palsy. Dev Med Child Neurol 1980;22(6):755-67.
20. Pinder RM, Brogden RN, Speight TM, Avery GS. Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1977;13(1):3-23.
21. Meythaler JM, Guin-Renfroe S, Johnson A, Brunner RM. Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch Phys Med Rehab 2001;82(9):1155-63.
22. Goldman JG, Comella CL. Treatment of dystonia. Clin Neuropharmacol 2003;26(2):102-8.
23. Greene PE, Fahn S. Baclofen in the treatment of idiopathic dystonia in children. Move Disord 1992; 7(1):48-52.
24. Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs 2000;59(3):487-95.
25. Chuang C, Fahn S, Frucht SJ. The natural history and treatment of acquired hemidystonia: report of 33 cases and review of the literature. J Neurol Neurosurg Psychiatr 2002;72(1):59-67.
26. Pranzatelli MR. Oral pharmacotherapy for the movement disorders of cerebral palsy. J Child Neurol 1996;11(Suppl 1):S13-22.
27. Albright AL, Gilmartin R, Swift D, Krach LE, Ivanhoe CB, McLaughlin JF. Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. J Neurosurg 2003;98(2):291-5.
28. Albright AL, Barry MJ, Shafton DH, Ferson SS. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 2001;43(10):652-7.
29. Campbell WM, Ferrel A, McLaughlin JF, Grant GA, Loeser JD, Graubert C, et al. Long-term safety and efficacy of continuous intrathecal baclofen. Dev Med Child Neurol 2002;44(10):660-5.
30. Mauriello JA. The role of botulinum toxin type A (BOTOX®) in the management of blepharospasm and hemifacial spasm. In: Brin MF, Hallett M, Jankovic J, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott, Williams & Wilkins; 2002. p. 197-205.
31. Bressman SB. Dystonia update. Clin Neuropharmacol 2000;23(5):239-51.
32. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48(2):358-62.
33. Manji H, Howard RS, Miller DH, Hirsch NP, Carr L, Bhatia K, et al. Status dystonicus: the syndrome and its management. Brain 1998;121:243-52.
34. Lucetti C, Nuti A, Gambaccini G, Bernardini S, Brotini S, Manca ML, et al. Mexiletine in the treatment of torticollis and generalized dystonia. Clin Neuropharmacol 2000;23(4):186-9.
35. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48(2):358-62.
36. Marsden CD, Marion MH, Quinn N. The treatment of severe dystonia in children and adults. J Neurol Neurosurg Psychiatr 1984;47(11):1166-73.
37. Fahn S. High dosage anticholinergic therapy in dystonia. Neurology 1983;33(10):1255-61.
38. Burke RE, Fahn S. Double-blind evaluation of trihexyphenidyl in dystonia. Adv Neurol 1983;37:189-92.
39. Hoon AH Jr, Freese PO, Reinhardt EM, Wilson MA, Lawrie WT Jr, Harryman SE, et al. Age-dependent effects of trihexyphenidyl in extrapyramidal cerebral palsy. Pediatr Neurol 2001;25(1):55-8.
40. Fletcher NA, Thompson PD, Scadding JW, Marsden CD. Successful treatment of childhood onset symptomatic dystonia with levodopa. J Neurol Neurosurg Psychiatr 1993;56(8):865-7.
41. Nygaard TG, Waran SP, Levine RA, Naini AB, Chutorian AM. Dopa-responsive dystonia simulating cerebral palsy. Pediatr Neurol 1994;11(3):236-40.